Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Published:2020-07 Issue:7 Volume:21 Page:923-934
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Blay Jean-Yves,Serrano César,Heinrich Michael C,Zalcberg John,Bauer Sebastian,Gelderblom Hans,Schöffski Patrick,Jones Robin L,Attia Steven,D'Amato Gina,Chi Ping,Reichardt Peter,Meade Julie,Shi Kelvin,Ruiz-Soto Rodrigo,George Suzanne,von Mehren Margaret

Publisher

Elsevier BV

Subject

Oncology

Reference36 articles.

1. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors;Hirota;Science,1998

2. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor;Heinrich;J Clin Oncol,2003

3. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels

4. Stivarga,2017

5. Long-term survival in a phase III trial of sunitinib in imatinib-resistant/-intolerant gastrointestinal stromal tumor with novel statistical analysis to account for crossover;Garrett,2008

Cited by 264 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations;Future Oncology;2024-09-04

2. Surgical Management of Gastric Gastrointestinal Stromal Tumors;Surgical Clinics of North America;2024-09

3. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial;The Lancet Oncology;2024-09

4. Effect and safety of ripretinib in the treatment of advanced gastrointestinal stromal tumor: A systematic review and meta-analysis;World Journal of Clinical Oncology;2024-08-24

5. Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research;Global Medical Genetics;2024-08-22